Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;58(10):6287-9.
doi: 10.1128/AAC.03469-14. Epub 2014 Jul 28.

Population pharmacokinetics of abacavir in pregnant women

Floris Fauchet  1 , Jean-Marc Treluyer  2 , Laure-Helene Préta  3 , Elodie Valade  4 , Emmanuelle Pannier  5 , Saik Urien  6 , Déborah Hirt  2
Affiliations

Population pharmacokinetics of abacavir in pregnant women

Floris Fauchet et al. Antimicrob Agents Chemother. 2014 Oct.

Abstract

For the first time, a population approach was used to describe abacavir (ABC) pharmacokinetics in HIV-infected pregnant and nonpregnant women. A total of 266 samples from 150 women were obtained. No covariate effect (from age, body weight, pregnancy, or gestational age) on ABC pharmacokinetics was found. Thus, it seems unnecessary to adapt the ABC dosing regimen during pregnancy.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Visual predictive check: comparison between the 5th (lower dashed line), 50th (solid line), and 95th (upper dashed line) percentiles obtained from 1,000 simulations and the observed plasma ABC concentrations (open circles) in pregnant women (A) and nonpregnant women (B). The model predictions and observations have been normalized to the median ABC dose, 600 mg.
See this image and copyright information in PMC

References

    1. World Health Organization. 2013. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization, Geneva, Switzerland - PubMed
    1. Zhao W, Cella M, Della Pasqua O, Burger D, Jacqz-Aigrain E, Pediatric European Network for Treatment of AIDS (PENTA) 15 Study Group 2012. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers. Br. J. Clin. Pharmacol. 73:641–650. 10.1111/j.1365-2125.2011.04121.x - DOI - PMC - PubMed
    1. Capparelli EV, Englund JA, Connor JD, Spector SA, McKinney RE, Palumbo P, Baker CJ. 2003. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J. Clin. Pharmacol. 43:133–140. 10.1177/0091270002239821 - DOI - PubMed
    1. Jullien V, Tréluyer J-M, Chappuy H, Dimet J, Rey E, Dupin N, Salmon D, Pons G, Urien S. 2005. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients. Br. J. Clin. Pharmacol. 59:183–188. 10.1111/j.1365-2125.2004.02259.x - DOI - PMC - PubMed
    1. Moyle GJ, DeJesus E, Cahn P, Castillo SA, Zhao H, Gordon DN, Craig C, Scott TR, Ziagen Once-Daily in Antiretroviral Combination Therapy (CNA30021) Study Team 2005. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J. Acquir. Immune Defic. Syndr. 38:417–425. 10.1097/01.qai.0000147521.34369.c9 - DOI - PubMed

LinkOut - more resources